ARDM - Aradigm Corporation

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.5300
-0.0400 (-2.5478%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close1.5700
Open1.5600
Bid1.1400 x 100
Ask1.5700 x 500
Day's Range1.5200 - 1.5800
52 Week Range0.7800 - 7.3500
Volume39,554
Avg. Volume197,565
Market Cap22.272M
Beta1.06
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date1996-03-01
1y Target EstN/A
Trade prices are not sourced from all markets
  • Associated Press29 days ago

    Aradigm reports 4Q loss

    On a per-share basis, the Hayward, California-based company said it had a loss of 28 cents. The specialty pharmaceutical company posted revenue of $2.4 million in the period. For the year, the company ...

  • Aradigm Files MAA for Bronchiectasis Candidate in the EU
    Zackslast month

    Aradigm Files MAA for Bronchiectasis Candidate in the EU

    Aradigm (ARDM) submits regulatory applications for its bronchiectasis candidate, Linhaliq, in the EU. A response from the EMA is awaited within 21 days to notify if the filing is complete.

  • Can Aradigm Corporation (NASDAQ:ARDM) Improve Your Portfolio Returns?
    Simply Wall St.2 months ago

    Can Aradigm Corporation (NASDAQ:ARDM) Improve Your Portfolio Returns?

    If you are looking to invest in Aradigm Corporation’s (NASDAQ:ARDM), or currently own the stock, then you need to understand its beta in order to understand how it can affectRead More...

  • Market Exclusive3 months ago

    Biotech Movers: Aradigm Corporation, Theravance Biopharma, Inc. and Mylan NV

    Aradigm Corporation (NASDAQ:ARDM), Theravance Biopharma, Inc. (NASDAQ:TBPH) and Mylan NV (NASDAQ:MYL) are all hitting headlines with each putting out an update relating to one of their respective development programs. Here’s a look at the news and what it means for all three companies. Aradigm This one is rooted in the release of a regulatory update […] The post Biotech Movers: Aradigm Corporation, Theravance Biopharma, Inc. and Mylan NV appeared first on Market Exclusive.

  • MarketWatch3 months ago

    Aradigm's stock plunges to lead Nasdaq losers after Linhaliq's NDA fails to get approved

    Shares of Aradigm Corp. plunged 21% toward a four-month low, after the drug maker said the Food and Drug Administration informed that company that its new drug application (NDA) for its lung infection ...

  • Aradigm's Bronchiectasis Candidate Has Negative FDA Vote
    Zacks3 months ago

    Aradigm's Bronchiectasis Candidate Has Negative FDA Vote

    The FDA panel votes against the approval of Aradigm's (ARDM) Linhaliq for treatment of non-cystic fibrosis bronchiectasis. A response from the regulatory agency is expected on Jan 26, 2018.

  • Market Exclusive3 months ago

    Biotech Updates: Aradigm Corporation & Puma Biotechnology

    Aradigm Corporation (NASDAQ:ARDM) and Puma Biotechnology, Inc. (NASDAQ:PBYI) both served up key updates in the biotechnology space this week, with each relating to a respective in-house development program. Here’s what happened with each company and what comes next for both. Aradigm Aradigm announced on Thursday that the FDA Antimicrobial Drugs Advisory Committee did not recommend […] The post Biotech Updates: Aradigm Corporation & Puma Biotechnology appeared first on Market Exclusive.

  • Where Aradigm Corporation (NASDAQ:ARDM) Stands In Terms Of Earnings Growth Against Its Industry
    Simply Wall St.4 months ago

    Where Aradigm Corporation (NASDAQ:ARDM) Stands In Terms Of Earnings Growth Against Its Industry

    When Aradigm Corporation (NASDAQ:ARDM) announced its most recent earnings (30 September 2017), I compared it against two factor: its historical earnings track record, and the performance of its industry peersRead More...

  • The Zacks Analyst Blog Highlights: Synergy Pharmaceuticals, Aradigm and Sucampo Pharmaceuticals
    Zacks4 months ago

    The Zacks Analyst Blog Highlights: Synergy Pharmaceuticals, Aradigm and Sucampo Pharmaceuticals

    The Zacks Analyst Blog Highlights: Synergy Pharmaceuticals, Aradigm and Sucampo Pharmaceuticals

  • 3 Biotech and Pharma Stocks with FDA Catalysts this January
    Zacks4 months ago

    3 Biotech and Pharma Stocks with FDA Catalysts this January

    2017 saw the FDA approving 46 novel drugs as well as path-breaking treatments like Novartis's (NVS) Kymriah and Gilead's Yescarta. Here is a look at three companies expecting a decision this January.

  • Benzinga4 months ago

    Attention Biotech Investors: Brace For These January PDUFA Events

    The biotech sector rebounded in 2017, with the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB ) rallying more than 21 percent. This follows an underwhelming performance in 2016, when the IBB lost ...

  • Capital Cube4 months ago

    ETFs with exposure to Aradigm Corp. : December 27, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Aradigm Corp. Here are 5 ETFs with the largest exposure to ARDM-US. Comparing the performance and risk of Aradigm Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Capital Cube5 months ago

    ETFs with exposure to Aradigm Corp. : December 1, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Aradigm Corp. Here are 5 ETFs with the largest exposure to ARDM-US. Comparing the performance and risk of Aradigm Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Capital Cube5 months ago

    ETFs with exposure to Aradigm Corp. : November 20, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Aradigm Corp. Here are 5 ETFs with the largest exposure to ARDM-US. Comparing the performance and risk of Aradigm Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Capital Cube5 months ago

    ETFs with exposure to Aradigm Corp. : November 8, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Aradigm Corp. Here are 5 ETFs with the largest exposure to ARDM-US. Comparing the performance and risk of Aradigm Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Aradigm (ARDM) Shares March Higher, Can It Continue?
    Zacks6 months ago

    Aradigm (ARDM) Shares March Higher, Can It Continue?

    As of late, it has definitely been a great time to be an investor in Aradigm Corporation (ARDM).

  • Can Aradigm Corporation (ARDM) Improve Your Portfolio Returns?
    Simply Wall St.6 months ago

    Can Aradigm Corporation (ARDM) Improve Your Portfolio Returns?

    If you are looking to invest in Aradigm Corporation’s (NASDAQ:ARDM), or currently own the stock, then you need to understand its beta in order to understand how it can affectRead More...

  • Associated Press8 months ago

    Aradigm posts 2Q profit

    The Hayward, California-based company said it had net income of 7 cents per share. The specialty pharmaceutical company posted revenue of $7.7 million in the period. The company's shares closed at $1.37. ...

  • Associated Press11 months ago

    Aradigm reports 1Q loss

    The Hayward, California-based company said it had a loss of 25 cents per share. The specialty pharmaceutical company posted revenue of $1.7 million in the period. The company's shares closed at 90 cents. ...